TEAD-IN-19

• Description :

  TEAD-IN-19 (Compound 1l) is a transcriptional inhibitor of TEAD, exhibiting inhibition rates of 38.5%, 36.2%, 57.8%, and 71.3% against TEAD1, TEAD2, TEAD3, and TEAD4, respectively, at a concentration of 10 μM. TEAD-IN-19 shows potent anti-proliferative and anti-migratory activities in prostate cancer cell lines and significantly reduces the expression of TEAD-regulated downstream genes. TEAD-IN-19 holds promise for research in the field of cancer therapy[1].

• UNSPSC :

  12352005

• Target :

  YAP

• Related Pathways :

  Stem Cell/Wnt

• Field of Research :

  Cancer

• Smiles :

  CN(C1=CC=CC=C1C(O)=O)C(C=C2)=CC=C2NC(C=C3)=C(Cl)C=C3C4567C89%10C%11%12(C%10%136(C)C%14%15%167)C%17%13%16C%11%18%19C%128%20C49%21C%22%155C%18%17%14C%19%20%21%22

• Molecular Formula :

  C33H19ClN2O2

• Molecular Weight :

  510.97

• References & Citations :

  [1]Li C, et al. Discovery and biological evaluation of carborane-containing derivatives as TEAD auto palmitoylation inhibitors. Bioorg Med Chem Lett. 2025 Feb 24;121:130155.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported